news
Decision upheld in Merck hepatitis C drugs patent case
A US appeals court has upheld a ruling that threw out a $2.54 billion jury verdict Merck won against Gilead over hepatitis C treatments.
List view / Grid view
Patents
Filter the results
news
China’s drug bulk-buy programme has been expanded
China has expanded a pilot drug bulk-buying programme to almost the entire country which is adding pressure on pharma companies.
news
Mylan generic of lung cancer drug Alimta approved
Mylan NV's generic version Eli Lilly and Co’s lung cancer drug, Alimta, has been given tentative approval by the FDA.
article
Hitting the target – refining anticancer nanomedicine development
Mahfoozur Rahman and Sarwar Beg explain why we need to change tack from traditional formulation-driven development to a target-based approach in order to increase success with anticancer nanomedicine in the clinic.
news
Antibody drug conjugates market to be worth $15bn by 2030
Antibody drug conjugates are presently recognised as a potent class of targeted anticancer therapies which will result in growth in the market.
news
Amgen patent claims invalidated by US district court
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
news
US appeals court overturns patent case for Jevtana
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
news
Amgen wins court patent ruling over Sandoz biosimilar
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
news
US court rules in favour of Lilly in Alimta® patent lawsuit
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy's Laboratories and Hospira, Inc.
news
Amgen wins patent block on Sanofi drug rival
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
news
Patent litigation for adalimumab resolved in the US
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
news
Legal ruling confirms that ‘routine’ discoveries can be patented
In a ruling handed down by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent.
news
Discoveries made through ‘routine’ research can now be patentable
In a ruling handed down on 27 March 2019 by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be rewarded with a patent...
article
Expert view: The QC micro labs have grown to tackle new challenges
29 October 2018 | By Charles River
Timelines, budgets and regulatory constraints have grown alongside that of the Quality Control (QC) lab’s position in drug development. The main goal of the lab and more widely of the manufacturing industry is to increase safety for the end user and guarantee patients’ health...
